Vir Biotechnology (VIR.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec12

H.C. Wainwright Maintains Buy Rating for Vir Biotechnology with a Price Target of $15.00

11:42

Nov9

Vir Biotechnology Reports Positive Results for Chronic Hepatitis Delta Treatment SOLSTICE Trial

23:10

Nov6

Evercore ISI analyst maintains BUY rating for Vir Biotechnology

15:22

Vir Biotechnology released FY2025 Q3 earnings on November 5 After-Market EST, actual revenue USD 240 K (forecast USD 1.983 M), actual EPS USD -1.1742 (forecast USD -0.845)

00:00

Vir Biotechnology released FY2025 9 Months earnings on November 5 After-Market (EST), actual revenue USD 4.486 M, actual EPS USD -2.8556

00:00

Nov5

Vir Biotechnology reports Q3 revenue below IBES estimates and wider net loss

21:06

Schedules & Filings

Schedules

Filings

Nov5

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 240 K, Net Income -163.14 M, EPS -1.1742

Aug6

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 1.214 M, Net Income -110.96 M, EPS -0.8014

May7

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 3.032 M, Net Income -120.97 M, EPS -0.8799

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change